Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906940 | 0.84 | IGF1R (0.34) | KDRIGF1RKDM4EALDH1A1HPGD | |
| SCHEMBL2907397 | 0.82 | TRPC5 (0.37) | QPCTKDRIGF1RKDM4EALDH1A1 | |
| SCHEMBL2901473 | 0.81 | NTRK1 (0.42) | KDRIGF1RKDM4EALDH1A1HPGD | |
| SCHEMBL2907955 | 0.80 | ADRA1A (0.48) | KDRIGF1RSLC2A1 | |
| SCHEMBL2901732 | 0.79 | EGFR (0.41) | KDRIGF1RSMN1; SMN2SLC2A1ELANE | |
| SCHEMBL2907882 | 0.79 | POLB (0.44) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL2908139 | 0.79 | KDR (0.34) | KDRKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2903153 | 0.75 | USP1 (0.35) | KDRNTRK1 | |
| SCHEMBL2904800 | 0.75 | EGFR (0.50) | KDRIGF1RALDH1A1SLC2A1 | |
| SCHEMBL2908752 | 0.72 | SLC2A1 (0.39) | KDRIGF1RKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | claimed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | claimed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | claimed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | claimed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | claimed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | QPCT 1518/4885KDR 3891/4885IGF1R 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.